Synlogic Inc. (SYBX) and Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) Comparing side by side

Synlogic Inc. (NASDAQ:SYBX) and Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) are two firms in the Biotechnology that compete against each other. Below is a comparison of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Synlogic Inc. 7 31.00 N/A -2.00 0.00
Eiger BioPharmaceuticals Inc. 12 0.00 N/A -3.84 0.00

In table 1 we can see Synlogic Inc. and Eiger BioPharmaceuticals Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Synlogic Inc. 0.00% -38.9% -33.6%
Eiger BioPharmaceuticals Inc. 0.00% -121.2% -71.8%

Risk and Volatility

A beta of 2.36 shows that Synlogic Inc. is 136.00% more volatile than Standard and Poor’s 500. Eiger BioPharmaceuticals Inc.’s 1.00% less volatile than Standard and Poor’s 500 volatility due to the company’s 0.99 beta.

Liquidity

11.5 and 11.5 are the respective Current Ratio and a Quick Ratio of Synlogic Inc. Its rival Eiger BioPharmaceuticals Inc.’s Current and Quick Ratios are 8.2 and 8.2 respectively. Synlogic Inc. has a better chance of clearing its pay short and long-term debts than Eiger BioPharmaceuticals Inc.

Analyst Ratings

Ratings and Recommendations for Synlogic Inc. and Eiger BioPharmaceuticals Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Synlogic Inc. 1 0 0 1.00
Eiger BioPharmaceuticals Inc. 0 0 0 0.00

Synlogic Inc.’s downside potential currently stands at -22.78% and an $2 consensus price target.

Insider and Institutional Ownership

Synlogic Inc. and Eiger BioPharmaceuticals Inc. has shares held by institutional investors as follows: 82.8% and 76.2%. Insiders held roughly 25.2% of Synlogic Inc.’s shares. On the other hand, insiders held about 0.4% of Eiger BioPharmaceuticals Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Synlogic Inc. -9.95% -40.13% -35.81% -25.4% -39.74% -19.97%
Eiger BioPharmaceuticals Inc. 0.73% 0.64% 2.98% -19.14% 10.15% 8.96%

For the past year Synlogic Inc. had bearish trend while Eiger BioPharmaceuticals Inc. had bullish trend.

Summary

Synlogic Inc. beats on 6 of the 8 factors Eiger BioPharmaceuticals Inc.

Synlogic, Inc. develops synthetic biotic medicines for the treatment of patients with urea cycle disorder and phenylketonuria. The company is based in Cambridge, Massachusetts.

Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. Its product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus (HDV) infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. The company was founded in 2008 and is headquartered in Palo Alto, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.